GlassScriptPhysician profile
Frederick N Lobati
NPI 1306823273
$221.70
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $74.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $45.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.35 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.79 | 2019-2020 | |
| Abbott Laboratories | $17.10 | 2019 | |
| Irhythm Technologies, INC. | $12.74 | 2019 | |
| Medtronic Vascular, INC. | $12.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.81 | 2020 | |
| Chiesi USA, INC. | $11.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Lobati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.